Global Botulinum Toxin Market Will Reach $ 7.9 Billion By 2026

FACTS AT A GLANCE
Edition: 19; Published: April 2021
Executive engagements: 702
Company: 28 – Players Covered include AbbVie; Daewoong Pharmaceutical Co., Ltd .; HUGEL-Pharma; Ipsen Group; Medy-Tox Inc .; Merz Pharma GmbH & Co. KGaA; Metabiologics, Inc .; Revance Therapeutics, Inc .; US WorldMeds and others.
Coverage: All major regions and key segments
Segments: Product (Type A, Type B); Application (therapeutics, aesthetics); End use (specialty and dermatology clinics, hospitals and clinics, other end uses)
Geographies: World; United States; Canada; Japan; China; Europe; France; Germany; Italy; UNITED KINGDOM; Spain; Russia; the rest of Europe; Asia Pacific; Australia; India; South Korea; the rest of Asia Pacific; Latin America; Rest of the world.

Free Project Preview – This is an ongoing global program. Check out our research program before making a purchase decision. We offer free access to qualified executives in the areas of strategy, business development, sales and marketing as well as product management at selected companies. Previews provide insider access to business trends; competitive brands; Domain expert profiles; and market data templates and much more. You can also create your own bespoke report using our MarketGlass ™ platform, which offers thousands of bytes of data, without the need to purchase our report. Registration preview

ABSTRACT-

Reaching Global Botulinum Toxin Market $ 7.9 billion by 2026
Botulinum toxin, a neurotoxin produced by the bacterium Clostridium botulinum, is able to inhibit the release of acetylcholine, which leads to muscle relaxation. Manufactured under controlled laboratory conditions and given in extremely small therapeutic doses, BTX is given intravenously only to the affected area. The growth on the world market is driven by the growing demand in medical-therapeutic and cosmetic applications. The growing acceptance of injectable facial injections such as BTX for facial aesthetics in adults and the approval of therapeutic BTX for the treatment of an expanded range of indications are expected to fuel market expansion. The constant development and introduction of new products to improve aesthetics and the growing demand for minimally invasive treatments in cosmetics and therapeutic applications are fueling market demand. In the field of neuromuscular therapeutics, the use of botulinum toxin is being driven by the increasing incidence of movement-related disorders and the growing number of patients with muscle cramps. In addition, new clinical indications of botulinum toxin such as the treatment of nystagmus, stridor, palatal myoclonus, scoliosis, co-convulsions after lesions of the brachial plexus (birth-related) and gait freeze (Parkinson’s) have helped to further strengthen growth in this area.

In the midst of the COVID-19 crisis, the global botulinum toxin market is on the rise. estimated $ 4.9 billion in 2020 is expected to reach a revised size of $ 7.9 billion until 2026 with a CAGR of 8.2% in the analysis period. Type A, one of the segments analyzed in the report, is expected to have 8.2% CAGR and reach a record $ 8.5 billion until the end of the analysis period. After a thorough analysis of the business impact of the pandemic and its triggered economic crisis, the Type B segment growth will be adjusted to a revised CAGR of 6.9% for the next 7 year period. Botulinum toxin type A is used in the treatment of movement disorders, vocal cord dysfunction, and obesity, and is also used as a medical aid in stomach cancer. The growth of botulinum toxin type A is being driven by its increasing use in the treatment of muscle spasms in cerebral palsy and neurogenic bladder diseases in children. Type B is used for various muscle-related diseases. Botulinum neurotoxin type B was approved by the FDA in 2000 for the treatment of adults with cervical dystonia to reduce the severity of abnormal head posture and neck pain associated with cervical dystonia.

The US market is estimated at $ 3.1 billion in 2021, while China is expected to reach $ 665 million by 2026
The US botulinum toxin market is estimated at $ 3.1 billion in 2021. China, the second largest economy in the world, is expected to reach a market size of $ 665 million by 2026 with a CAGR of 14.8% in the analysis period. Other notable geographic markets include Japan and Canada, which will grow by 8.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow about 9.1% CAGR. The United States represents the largest regional market, which is mainly driven by the growing approval of new therapeutic indications. The increasing focus on improving appearance, rising disposable incomes and the resulting increase in demand for cosmetic procedures are also spurring growth. The increasing demand for non-invasive or minimally invasive aesthetic treatments is also contributing to the growth of the botox market in the United States. Europe also offers attractive opportunities for the botox market due to the presence of a large number of cosmetic manufacturers. The rapid improvement in socio-economic conditions and the increase in medical tourism, particularly in Asian countries, offer favorable prospects for botulinum toxin in Asia Pacific Region. More

MarketGlass ™ platform
Our MarketGlass ™ platform is a free, full-stack knowledge center that can be customized to meet the intelligence needs of today’s busy business leaders! This influencer-controlled interactive research platform is the heart of our primary research activities and is based on the unique perspectives of the participating executives worldwide. Features include – enterprise-wide peer-to-peer collaboration; previews of research programs relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke reporting; Monitor market trends; competitive brands; Create and publish blogs and podcasts with our primary and secondary content; Track domain events worldwide; and much more. Client companies have complete insider access to the project data stacks. Currently used by over 67,000 domain experts worldwide.

Our platform is free for qualified executives and accessible through our website http://www.StrategyR.com or through our recently released mobile application for iOS or Android

About Global Industry Analysts, Inc. & StrategyR ™
Global Industry Analysts, Inc. (www.strategyr.com) is a renowned market research publisher and the world’s only influencer-driven market research company. GIA proudly serves more than 42,000 customers from 36 countries and has been known for accurate market and industry forecasting for over 33 years.

CONTACTS:
Zak Ali
Director, corporate communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
http://www.StrategyR.com
E-mail: [email protected]

LEFT
Join our panel of experts
https://www.strategyr.com/Panelist.asp

Connect with us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

Follow us on Twitter
https://twitter.com/marketbytes

Journalists & media
[email protected]

SOURCE Global Industry Analysts, Inc.

https://platform.twitter.com/widgets.js

The following post Global Botulinum Toxin Market Will Reach $ 7.9 Billion By 2026 was seen on AmericanChiropractors

from American Chiropractors Directory and News – Feed https://www.americanchiropractors.org/neck-pain/global-botulinum-toxin-market-will-reach-7-9-billion-by-2026/

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s